Paragon Private Wealth Management LLC Makes New Investment in DexCom, Inc. $DXCM

Posted by Brian Himes on Sep 3rd, 2026

Paragon Private Wealth Management LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,567 shares of the medical device company’s stock, valued at approximately $712,000.

Several other institutional investors and hedge funds have also modified their holdings of DXCM. Brighton Jones LLC raised its stake in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares in the last quarter. Empowered Funds LLC increased its holdings in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth raised its position in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after acquiring an additional 258 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM opened at $89.69 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock’s 50 day moving average price is $80.47 and its two-hundred day moving average price is $72.10. The firm has a market capitalization of $33.85 billion, a P/E ratio of 35.45, a price-to-earnings-growth ratio of 1.51 and a beta of 1.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.48 earnings per share. On average, equities analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 65,777 shares of company stock valued at $4,950,714 in the last quarter. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent research reports. Barclays restated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Royal Bank Of Canada increased their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Bank of America cut their target price on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Finally, Wall Street Zen downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Read Our Latest Research Report on DexCom

DexCom Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.